Understand the source comparison
Peptide Protocol Comparison for Hip Labral Pathology
BPC-157 VEGF/FGF-2 upregulation → angiogenesis and fibroblast migration to injury zone 250–500 mcg daily SC for 8–12 weeks Animal tendon models only; no human RCTs for labral tears Begin week 2–3 post-injury; pair with progressive loading PT TB-500 Actin-bindi
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- VEGF/FGF-2 upregulation → angiogenesis and fibroblast migration to injury zone
- 250–500 mcg daily SC for 8–12 weeks
- Animal tendon models only; no human RCTs for labral tears
- Begin week 2–3 post-injury; pair with progressive loading PT
- TB-500
- Actin-binding peptide → cell migration, reduced scar tissue formation, improved tensile strength
- 2–5 mg twice weekly × 4 weeks, then weekly maintenance
- Animal ligament/muscle models; case series in human tendon injuries
- Most effective in proliferative phase (weeks 2–8); limited benefit if started after 12 weeks
- CJC-1295/Ipamorelin
- GH secretagogue → systemic IGF-1 elevation → proteoglycan synthesis and tissue remodeling
- 100–200 mcg each, 5 days/week before bed for 12–16 weeks
- Indirect mechanism; no labral-specific data; general connective tissue studies
- Adjunctive to direct-acting peptides; benefits are systemic and slower to manifest
- Before initiating any peptide protocol, verify peptide purity through certificate of analysis (COA) from the supplier. Compounded peptides without third-party HPLC testing may contain impurities, incorrect concentrations, or degraded product. Rendering the protocol ineffective regardless of dosing accuracy.